Synopsis: Zota Health Care Limited has signed a Memorandum of Understanding (MoU) to acquire an 80 percent stake in Globotask IT Consultancy Services Private Limited for Rs. 25 lakh. The acquisition is aimed at strengthening the company’s digital capabilities through cloud-based software, ERP solutions, mobile applications and IT services.
Shares of Zota Health Care Limited are likely to remain in focus after the company announced that it has entered into a Memorandum of Understanding (MoU) to acquire an 80 percent stake in Globotask IT Consultancy Services Private Limited (GITCL).
Zota Health Care Limited has a total market capitalization of approximately Rs. 4,516.09 crore. The company’s shares were trading at Rs. 1303.90 apiece on the stock exchange, down by 0.28 percent during the session. The stock has gained 4.77 percent over the last five trading sessions, while it has gained 9.33 percent over the last month. The stock touched a 52-week high of Rs. 1740 and a 52-week low of Rs. 925.
According to the company’s regulatory filing, Zota Health Care will acquire 8,000 equity shares, representing an 80 percent stake in Globotask IT Consultancy Services Private Limited, for an aggregate consideration of Rs. 25 lakh.
The acquisition will be carried out through the purchase of equity shares from the existing promoters and shareholders of Globotask, namely Digbijoy Sharma, Subhro Das and Rohit P. Das. The company clarified that the transaction does not involve any related parties and that neither the promoter group nor group companies have any interest in the target company.
The primary objective of the acquisition is to strengthen Zota Health Care’s digital infrastructure by leveraging Globotask’s expertise in cloud-based software development android and iOS application development, website development and customized Enterprise Resource Planning (ERP) software. The IT solutions are expected to support Zota Health Care as well as its subsidiaries in improving operational efficiency and accelerating digital transformation.
The acquisition reflects the growing trend of healthcare companies investing in technology to streamline business processes, enhance customer engagement and improve supply chain and enterprise management systems. As pharmaceutical companies continue to digitize operations, investments in cloud platforms, ERP systems and customized software solutions are becoming increasingly important for improving productivity and scalability.
For investors, while the transaction value of Rs. 25 lakh is relatively modest, the strategic importance lies in the potential integration of technology capabilities into the company’s core pharmaceutical operations. Digital platforms can help improve inventory management, distribution efficiency, sales tracking and customer relationship management while supporting future business expansion.
India’s healthcare technology market has witnessed strong growth in recent years, driven by increasing adoption of digital health solutions, cloud computing, enterprise software and automation across the pharmaceutical and healthcare sectors. Companies integrating technology into their business models are expected to benefit from improved operational efficiency and enhanced competitiveness.
Incorporated in 2000, Zota Health Care Limited is engaged in the manufacturing, marketing and export of pharmaceutical, ayurvedic, nutraceutical and over-the-counter (OTC) products. The company serves domestic as well as international markets, including countries across Asia, Africa, Russia and Latin America, with a diversified portfolio of healthcare products.
The proposed acquisition of Globotask IT Consultancy Services is expected to strengthen Zota Health Care’s technology capabilities and support its long-term digital transformation strategy while enhancing operational efficiencies across its business.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
